Certain inventions disclosed herein relate to treating a carotid artery. For example, a carotid artery may have a lesion or a partial occlusion that can be treated using the methods and apparatus disclosed herein.
Carotid angioplasty and stenting (CAS) is a minimally invasive approach for treating carotid stenoses. Since its introduction two decades ago, the use of CAS has steadily increased, with 8% of the 107,000 carotid procedures performed in Europe in 2001 utilizing CAS. The prospect of an outpatient procedure without the discomfort of a sizable neck incision appears to be driving patient decision making away from carotid endarterectomy, the standard procedure for carotid bifurcation disease for the past fifty years.
One disclosed embodiment comprises an apparatus for use in carotid angioplasty. The apparatus comprises a catheter having a distal end and a proximal end opposite the distal end, and first and second occlusive members, of which at least the first occlusive member is located on the catheter. The first and second occlusive members are configured to reverse the natural direction of blood flow in the internal carotid artery when the first occlusive member occludes the common carotid artery and the second occlusive member occludes the external carotid artery. The catheter has a first shaft portion extending proximally from the first occlusive member. The first shaft portion has a maximum cross-section sized to be insertable into the common carotid artery. The first shaft portion has a relatively short length suitable for transcervical access to the common carotid artery. The catheter has a blood entry port located distal of the first occlusive member. The apparatus further comprises a collection reservoir configured to be connected to the catheter and placed in passive fluid communication with the blood entry port.
Another disclosed embodiment comprises a method of treating a lesion in a carotid artery in a patient. The method comprises inserting a catheter into the carotid vasculature via a transcervical approach, and occluding blood flow in the common carotid artery and the external carotid artery, thus reversing the direction of natural blood flow in the internal carotid artery. The method further comprises allowing blood to flow into a blood entry port in the catheter, and passively collecting the blood in a reservoir.
Another disclosed embodiment comprises an apparatus for use in carotid angioplasty. The apparatus comprises a catheter having a distal end and a proximal end opposite the distal end, and first and second occlusive members, of which at least the first occlusive member is located on the catheter. The first and second occlusive members are configured to reverse the natural direction of blood flow in the internal carotid artery when the first occlusive member occludes the common carotid artery and the second occlusive member occludes the external carotid artery. The catheter has a first shaft portion extending proximally from the first occlusive member. The first shaft portion has a maximum cross-section sized to be insertable into the common carotid artery. The first shaft portion has a relatively short length suitable for transcervical access to the common carotid artery. The catheter has a blood entry port located distal of the first occlusive member. The apparatus further comprises a passive fluid conduit and a collection reservoir. The collection reservoir is configured to be connected to the catheter via the passive fluid conduit.
Another disclosed embodiment comprises a method for treating lesions in the carotid artery of a mammalian body. The method comprises transcervical access and blocking of blood flow through the common carotid artery, shunting blood from the internal carotid artery to the venous system of the mammalian body and treating the lesion in the carotid artery. The method may optionally further comprise blocking blood flow through the external carotid artery.
In the method, access to the carotid artery can optionally be obtained percutaneously, or via a cutdown incision, or with any suitable technique. The treating step of the method can optionally include dilating the lesion with a balloon. The treating step of the method can optionally include stenting the dilated lesion. The shunting step of the method can optionally include filtering the blood for debris. The blocking step of the method can optionally include occluding the external carotid artery with a balloon. The blocking step of the method can optionally include occluding the common carotid artery with a balloon. The blocking step of the method can optionally include clamping the common carotid artery. The introducing step of the method can optionally include positioning a single sheath with balloons to occlude the common and external carotid artery and a side port for deployment of an angioplasty balloon or stent. The blocking step of the method can optionally include introducing at least one catheter directly into the common carotid artery. The introducing step of the method can optionally include introducing first and second introducer sheaths directly into the common carotid artery. The introducing step of the method can optionally include introducing first and second balloon catheters directly into the common carotid artery.
Another disclosed embodiment comprises a method for treating lesions in the carotid artery. The method comprises transcervical access, blocking blood flow through the common carotid artery to allow safe treatment of the lesion and returning blood flow back to the carotid artery. The method may further comprise blocking blood flow through the external carotid artery.
In the method, the blood in the carotid artery may be actively withdrawn and returned to the carotid artery. In the method, access to the carotid artery can optionally be obtained percutaneously, or via a cutdown incision, or with any suitable technique. The treating step of the method can optionally include dilating the lesion with a balloon. The treating step of the method can optionally include stenting the dilated lesion. The shunting step of the method can optionally include filtering the blood for debris. The blocking step of the method can optionally include occluding the external carotid artery with a balloon. The blocking step of the method can optionally include occluding the common carotid artery with a balloon. The blocking step of the method can optionally include clamping the common carotid artery. The introducing step of the method can optionally include positioning a single sheath with balloons to occlude the common and external carotid artery and a side port for deployment of an angioplasty balloon or stent. The blocking step of the method can optionally include introducing at least one catheter directly into the common carotid artery. The introducing step of the method can optionally include introducing first and second introducer sheaths directly into the common carotid artery. The introducing step of the method can optionally include introducing first and second balloon catheters directly into the common carotid artery.
Another disclosed embodiment comprises a method for treatment of lesions in the carotid artery. The method comprises transcervical access, blocking blood flow through the common carotid artery and passive collection of blood and debris and subsequent return of filtered blood to the carotid artery. The method may further comprise blocking blood flow through the external carotid artery.
In the method, access to the carotid artery can optionally be obtained percutaneously, or via a cutdown incision, or with any suitable technique. The treating step of the method can optionally include dilating the lesion with a balloon. The treating step of the method can optionally include stenting the dilated lesion. The shunting step of the method can optionally include filtering the blood for debris. The blocking step of the method can optionally include occluding the external carotid artery with a balloon. The blocking step of the method can optionally include occluding the common carotid artery with a balloon. The blocking step of the method can optionally include clamping the common carotid artery. The introducing step of the method can optionally include positioning a single sheath with balloons to occlude the common and external carotid artery and a side port for deployment of an angioplasty balloon or stent. The blocking step of the method can optionally include introducing at least one catheter directly into the common carotid artery. The introducing step of the method can optionally include introducing first and second introducer sheaths directly into the common carotid artery. The introducing step of the method can optionally include introducing first and second balloon catheters directly into the common carotid artery.
Certain objects and advantages of the invention are described herein. Of course, it is to be understood that not necessarily all such objects or advantages may be achieved in accordance with any particular embodiment of the invention. Thus, for example, those skilled in the art will recognize that the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other objects or advantages as may be taught or suggested herein.
All of the embodiments summarized above are intended to be within the scope of the invention herein disclosed. However, despite the foregoing discussion of certain embodiments, only the appended claims (and not the present summary) are intended to define the invention. The summarized embodiments, and other embodiments of the present invention, will become readily apparent to those skilled in the art from the following detailed description of the preferred embodiments having reference to the attached figures, the invention not being limited to any particular embodiment(s) disclosed.
An approach called Transcervical Occlusion (of the CCA) and Proximal Shunting (TOPS) can be employed in carotid angioplasty.
In one embodiment, depicted in
After heparin (for example, about 70 IU/kg to about 100 IU/kg) is administered to increase the activated clotting time (to greater than 250 seconds, for example), a needle (not shown) is introduced directly into the CCA 12 above the position of a surgical clamp 14. Injection of contrast under fluoroscopy in the appropriate anterior oblique plane localizes the carotid bifurcation and the lesion 16 in a “worst view” magnified angiogram. A guidewire (not shown) is advanced to the distal carotid bulb 22 or to the external carotid artery 20. A first sheath 24 is advanced until the dilator (a component of the sheath not shown) straightens the tip of the guidewire and then the sheath 24 is advanced over the dilator to the distal CCA 13 or the external carotid artery (ECA) 20. Intracranial carotid angiography is performed (AP Towne and lateral view) to document any pre-existent intracranial arterial pathology and to evaluate collateral circulation.
The first sheath 24 can be placed directly in the CCA 12 parallel to a smaller second introducer sheath 26 placed with its tip in the distal CCA 13. A stitch may be placed around the entrance of the first sheath 24 and a vascular tourniquet (not shown) and umbilical tape (not shown) may be looped around the CCA to allow rapid hemostasis of the puncture site in the event of catheter dislodgement. A guidewire is directed into the ECA 20 through the first arterial sheath 24 and a balloon catheter 25 is used to occlude the proximal ECA 21. Occlusion of the ECA 20 and reversal of blood flow in the internal carotid artery (ICA) 42 can be verified with angiography after clamping the CCA 12.
A sidearm 30 of the first sheath 24 is connected to a filter 34 with a holder apparatus (not shown) that is attached to a sidearm 38 of a third sheath 28 in fluid communication with the internal jugular vein 40. This configuration forms a shunt 32. With the surgical clamp 14 applied to the CCA 12, retrograde flow of contrast from the internal carotid artery (ICA) 42 into the internal jugular vein 40 through the shunt 32 can be confirmed using fluoroscopy or duplex ultrasound. The carotid lesion 16 is crossed with a guidewire 27 from the second sheath 26 under flow reversal cerebral protection and the lesion 16 is dilated with a balloon 29.
If rapid retrograde flow of contrast is not seen with initiation of the shunt 32, forceful aspiration of blood using a syringe (for example a 20 cc syringe) through the first sheath 24 is performed, for example, after each angioplasty. Hence, retrograde passage of embolic material is provided. The blood is returned to the patient through a three way stopcock (for example, stopcock 44 and stopcock 46) attached to the shunt 32 or filter 34. A stent (for example an 8 or 10 mm×24 mm stent) can be deployed across the lesion 16 into the CCA 12. The stent can be serially post dilated with an angioplasty balloon (for example a 5 or 6 mm×2 cm angioplasty balloon).
Completion of cervical and intracranial carotid angiography is performed after releasing the external carotid occlusion balloon 25 and the common carotid clamp 14. Once satisfactory treatment of the lesion 16 is observed, the first arterial sheath 24 and second arterial sheath 26 are removed with simultaneous repair of the arterial punctures using previously placed exit site sutures.
In some embodiments, either or both of the sheaths 24, 26 may have an insertable length or first shaft portion extending proximally from the distal end of the sheath(s). Over the entirety of the insertable length, the sheath(s) 24, 26 have a cross-sectional size (e.g., about 6-8 French) which is suitable for insertion into the CCA 12. (Although the cross-sectional size need not be uniform along the insertable length, the maximum cross-sectional size along the insertable length should be suitable for insertion into the CCA.) In certain such embodiments, the insertable length is less than about 75 cm, less than about 50 cm, less than about 30 cm, or less than about 15 cm. In still other embodiments, the insertable length is between about 2 cm and about 25 cm, or between about 2 cm and about 15 cm. More generally, the insertable length may be relatively short as may be suitable for transcervical access to the CCA.
In some embodiments, one or both of the shafts 24a, 26a of the sheaths 24, 26 is constructed to be generally rigid. Advantageously, a rigid sheath 24/26 can be inserted into the CCA 12 without need to “ride” the sheath 24/26 over a guidewire. As another alternative either shaft 24a/26a may be made generally rigid but sufficiently malleable to permit the user to “pre-bend” the shaft 24a/26a, such that the shaft maintains the bent shape imparted by the user. With such a malleable shaft 24a/26a, the user can custom-shape the sheath 24/26 to fit the vasculature of the patient, and more easily manipulate the sheath 24/26 into position in the CCA 12. The pre-bend may be made based on the user's observations of the patient's carotid vasculature. A sheath 24/26 which is rigid and/or malleable as discussed above can be made from stainless steel or suitable soft metals, or any suitable polymeric materials.
In another embodiment, illustrated in
In some embodiments, the sheath 224 may have an insertable length or first shaft portion extending proximally from the balloon 252. Over the entirety of the insertable length, the sheath 224 has a cross-sectional size (e.g., about 6-8 French) which is suitable for insertion into the CCA 12. (Although the cross-sectional size need not be uniform along the insertable length, the maximum cross-sectional size along the insertable length should be suitable for insertion into the CCA.) In certain such embodiments, the insertable length is less than about 75 cm, less than about 50 cm, less than about 30 cm, or less than about 15 cm. In still other embodiments, the insertable length is between about 2 cm and about 25 cm, or between about 2 cm and about 15 cm. More generally, the insertable length may be relatively short as may be suitable for transcervical access to the CCA.
In some embodiments, the shaft 224a of the sheath 224 is constructed to be generally rigid. Advantageously, a rigid sheath 224 can be inserted into the CCA 12 without need to “ride” the sheath 224 over a guidewire. As another alternative the shaft 224a may be made generally rigid but sufficiently malleable to permit the user to “pre-bend” the shaft 224a, such that the shaft maintains the bent shape imparted by the user. With such a malleable shaft 224a, the user can custom-shape the sheath 224 to fit the vasculature of the patient, and more easily manipulate the sheath 224 into position in the CCA 12. The pre-bend may be made based on the user's observations of the patient's carotid vasculature. A sheath 224 which is rigid and/or malleable as discussed above can be made from stainless steel or suitable soft metals, or any suitable polymeric materials.
In a further embodiment, illustrated in
In one embodiment, the first balloon 352 has an inflated diameter of up to about 13 mm and the second balloon 325 has an inflated diameter of up to 6 mm. The balloons are preferably spaced about 2-6 cm apart on the sheath 324.
A sliding or removable sleeve 382 (see
A sheath equipped with the sleeve 382 may be useful, for example, for treating common carotid lesions (not shown) or treating internal carotid lesions when the ECA is occluded. In these cases, the sheath cannot be extended into the occluded ECA so only the very tip of the sheath 324 with the distal second balloon 325 is placed into and occludes the CCA 352. There is no need for a separate ECA occlusion balloon if the ECA is already occluded or severely narrowed with disease. Such a positioning of the sheath may result in the side opening 374 or hole in the sheath being external the patient. The side opening 374 is thus covered with the sleeve 382 to inhibit or prevent blood from spurting out of the sheath 324 onto the operative field.
An occluded ECA is not shown in
If the ECA is not occluded, the sleeve 382 can be either peeled away or slid away to allow the sheath 324 to be pushed farther distally through the incision and into the hole in the artery so that the second balloon 325 is positioned in the ECA 320. Such a placement of the sheath 324, as discussed above, permits deployment of the stent 329 through the sidehole 374 instead of through the end hole 373 of the sheath 324. The decision concerning where to place the tip of the sheath is made during the initial angiogram. As can be appreciated, such a sheath may also be useful for performing the procedure illustrated in
As indicated by flow arrow 372, a sidearm 330 of the sheath 324 can lead to a shunt such as the shunt 32 described above, a filter, a contrast injection/blood aspiration apparatus such as the apparatus 260 described above, a contrast reservoir such as the reservoir 264 described above, stopcocks, a venous sheath such as the sheath 28 of
In an alternative embodiment, the sheath 324 of
In some embodiments, the sheath 324 may have an insertable length or first shaft portion extending proximally from the first balloon 352. Over the entirety of the insertable length, the sheath 324 has a cross-sectional size (e.g., about 6-8 French) which is suitable for insertion into the CCA 12. (Although the cross-sectional size need not be uniform along the insertable length, the maximum cross-sectional size along the insertable length should be suitable for insertion into the CCA.) In certain such embodiments, the insertable length is less than about 75 cm, less than about 50 cm, less than about 30 cm, or less than about 15 cm. In still other embodiments, the insertable length is between about 2 cm and about 25 cm, or between about 2 cm and about 15 cm. More generally, the insertable length may be relatively short as may be suitable for transcervical access to the CCA.
In some embodiments, the shaft 324a of the sheath 324 is constructed to be generally rigid. Advantageously, a rigid sheath 324 can be inserted into the CCA 12 without need to “ride” the sheath 324 over a guidewire. As another alternative the shaft 324a may be made generally rigid but sufficiently malleable to permit the user to “pre-bend” the shaft 324a, such that the shaft maintains the bent shape imparted by the user. With such a malleable shaft 324a, the user can custom-shape the sheath 324 to fit the vasculature of the patient, and more easily manipulate the sheath 324 into position in the CCA 12. The pre-bend may be made based on the user's observations of the patient's carotid vasculature. A sheath 324 which is rigid and/or malleable as discussed above can be made from stainless steel or suitable soft metals, or any suitable polymeric materials.
Certain embodiments do not employ venous shunting. One such embodiment is illustrated in
After the period of cerebral protection is over and the natural direction of blood flow is restored (e.g., via deflation of the balloon(s) and/or release of the clamp), the collected blood can be returned to the patient's vasculature, e.g. via the CCA 12 and implanted sheath 24/224/324. To do this the valves 591 and 597 are closed, and the valve 590 is opened. The plunger 594 is then depressed to force the collected blood out of the reservoir 598, through the filter 568 and valve 590, and out through the blood outlet port 593. If a return line such as the arterial channel 486 is employed, the blood proceeds through the channel 486 and implanted sheath, and back into the CCA 12.
If desired a non-rigid overflow chamber (such as a ventilated bag) can be connected to the air outlet port 596 to collect any blood that overflows the reservoir 598. As yet another option, a metering valve (not shown) can be installed on the sidearm 30/230/330 (or between the sidearm and the reservoir 598) to adjust the blood flow rate into the reservoir 598, to account for patient-to-patient variation in natural arterial flow rates.
As a further option, a contrast reservoir (not shown) can be coupled to the return line/arterial channel downstream of the blood outlet port 593, via a “T” fitting or the like, to add contrast fluid as desired to the blood as it returns to the patient.
Additional embodiments comprise kits. A first kit comprises the apparatus of
Instead of or in addition to these short-length guidewires, any of the kits mentioned above may comprise a “bent” introducer needle with appropriate angulation to decrease the likelihood of backwall arterial puncture. The introducer needle may have a contrast injection sideport.
Although these inventions have been disclosed in the context of certain preferred embodiments and examples, it will be understood by those skilled in the art that the present invention extends beyond the specifically-disclosed embodiments to other alternative embodiments and/or uses of the inventions and obvious modifications and equivalents thereof. In addition, while a number of variations of the inventions have been shown and described in varying levels of detail, other modifications, which are within the scope of this invention, will be readily apparent to those of skill in the art based upon this disclosure. It is also contemplated that various combinations or subcombinations of the specific features and aspects of the embodiments may be made and still fall within the scope of the inventions. Accordingly, it should be understood that various features and aspects of the disclosed embodiments can be combined with or substituted for one another in order to form varying modes of the disclosed inventions. Thus, it is intended that the scope of the present invention herein disclosed should not be limited by the particular disclosed embodiments described above, but should be determined only by a fair reading of the claims that follow.
This application is a continuation of U.S. patent application Ser. No. 16/939,396, titled “Method and Apparatus for Treating an Arterial Lesion” filed Jul. 27, 2020 and is continuation of U.S. patent application Ser. No. 16/581,034, titled “Method and Apparatus for Treating an Arterial Lesion” filed Sep. 24, 2019, now U.S. Pat. No. 10,722,239, which is a continuation of U.S. patent application Ser. No. 16/256,229, titled “Method and Apparatus for Treating A Carotid Artery” filed Jan. 24, 2019, now U.S. Pat. No. 10,779,835, which is a continuation of U.S. patent application Ser. No. 15/168,786 titled “Method And Apparatus For Treating A Carotid Artery”, filed May 31, 2016, now U.S. Pat. No. 10,188,399, which is a continuation of U.S. patent application Ser. No. 14/622,310, titled “Method And Apparatus for Treating A Carotid Artery,” filed Feb. 13, 2015, now U.S. Pat. No. 9,526,504; which in turn is a continuation of U.S. patent application Ser. No. 14/508,354, titled “Method And Apparatus For Treating A Carotid Artery,” filed Oct. 7, 2014; now U.S. Pat. No. 9,662,118; which in turn is a continuation of U.S. patent application Ser. No. 12/966,974, titled “Method And Apparatus For Treating A Carotid Artery,” filed Dec. 13, 2010, now U.S. Pat. No. 8,870,805; which in turn is a continuation of U.S. patent application Ser. No. 10/996,301, titled “Method And Apparatus For Treating A Carotid Artery,” filed Nov. 22, 2004, now U.S. Pat. No. 7,998,104; which claims the benefit under 35 U.S.C. § 119(e) of the following U.S. Provisional applications: (1) U.S. Provisional Patent Application Ser. No. 60/524,069, filed Nov. 21, 2003, titled “Method And Apparatus For Carotid Angioplasty And Stenting Using Transcervical Occlusion And Protective Shunting;” (2) U.S. Provisional Patent Application Ser. No. 60/569,843, filed May 10, 2004, titled “Method And Apparatus For Carotid Angioplasty And Stenting Using Transcervical Occlusion And Protective Shunting;” and (3) U.S. Provisional Patent Application Ser. No. 60/587,067, filed Jul. 12, 2004, titled “Method And Apparatus For Carotid Angioplasty And Stenting Using Transcervical Occlusion And Protective Shunting.” Priority of the aforementioned filing dates is hereby claimed, and the disclosures of the Applications are hereby incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4301803 | Handa et al. | Nov 1981 | A |
4493707 | Ishihara | Jan 1985 | A |
4771777 | Horzewski et al. | Sep 1988 | A |
4840690 | Melinyshyn et al. | Jun 1989 | A |
4865581 | Lundquist et al. | Sep 1989 | A |
4921478 | Solano et al. | May 1990 | A |
4921479 | Grayzel | May 1990 | A |
5135484 | Wright | Aug 1992 | A |
5250060 | Carbo et al. | Oct 1993 | A |
5328470 | Nabel et al. | Jul 1994 | A |
5328471 | Slepian | Jul 1994 | A |
5380284 | Don Michael | Jan 1995 | A |
5429605 | Richling et al. | Jul 1995 | A |
5584803 | Stevens et al. | Dec 1996 | A |
5769821 | Abrahamson et al. | Jun 1998 | A |
5769830 | Parker | Jun 1998 | A |
5782800 | Yoon | Jul 1998 | A |
5833650 | Imran | Nov 1998 | A |
5876367 | Kaganov et al. | Mar 1999 | A |
5895399 | Barbut et al. | Apr 1999 | A |
5910154 | Tsugita et al. | Jun 1999 | A |
5916193 | Stevens et al. | Jun 1999 | A |
6090072 | Kratoska et al. | Jul 2000 | A |
6146370 | Barbut | Nov 2000 | A |
6152912 | Jansen et al. | Nov 2000 | A |
6161547 | Barbut | Dec 2000 | A |
6165199 | Barbut | Dec 2000 | A |
6206868 | Parodi | Mar 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6270477 | Bagaoisan et al. | Aug 2001 | B1 |
6295989 | Connors, III | Oct 2001 | B1 |
6306163 | Fitz | Oct 2001 | B1 |
6312444 | Barbut | Nov 2001 | B1 |
6364900 | Heuser | Apr 2002 | B1 |
6383172 | Barbut | May 2002 | B1 |
6413235 | Parodi | Jul 2002 | B1 |
6423032 | Parodi | Jul 2002 | B2 |
6423086 | Barbut et al. | Jul 2002 | B1 |
6454741 | Muni et al. | Sep 2002 | B1 |
6464664 | Jonkman et al. | Oct 2002 | B1 |
6471672 | Brown et al. | Oct 2002 | B1 |
6482172 | Thramann | Nov 2002 | B1 |
6527746 | Oslund et al. | Mar 2003 | B1 |
6533800 | Barbut | Mar 2003 | B1 |
6540712 | Parodi et al. | Apr 2003 | B1 |
6551268 | Kaganov et al. | Apr 2003 | B1 |
6555057 | Barbut et al. | Apr 2003 | B1 |
6558356 | Barbut | May 2003 | B2 |
6582396 | Parodi | Jun 2003 | B1 |
6582448 | Boyle et al. | Jun 2003 | B1 |
6595953 | Coppi et al. | Jul 2003 | B1 |
6595980 | Barbut | Jul 2003 | B1 |
6605074 | Zadno-Azizi et al. | Aug 2003 | B2 |
6623471 | Barbut | Sep 2003 | B1 |
6626886 | Barbut | Sep 2003 | B1 |
6632236 | Hogendijk | Oct 2003 | B2 |
6638245 | Miller et al. | Oct 2003 | B2 |
6645222 | Parodi et al. | Nov 2003 | B1 |
6652480 | Imran et al. | Nov 2003 | B1 |
6663652 | Daniel et al. | Dec 2003 | B2 |
6669721 | Bose et al. | Dec 2003 | B1 |
6673040 | Samson et al. | Jan 2004 | B1 |
6682505 | Bates et al. | Jan 2004 | B2 |
6695861 | Rosenberg et al. | Feb 2004 | B1 |
6702782 | Miller et al. | Mar 2004 | B2 |
6711436 | Duhaylongsod | Mar 2004 | B1 |
6736790 | Barbut et al. | May 2004 | B2 |
6755847 | Eskuri | Jun 2004 | B2 |
6783511 | Komtebedde et al. | Aug 2004 | B2 |
6830579 | Barbut | Dec 2004 | B2 |
6837881 | Barbut | Jan 2005 | B1 |
6840949 | Barbut | Jan 2005 | B2 |
6855136 | Dorros et al. | Feb 2005 | B2 |
6875231 | Anduiza et al. | Apr 2005 | B2 |
6878140 | Barbut | Apr 2005 | B2 |
6887227 | Barbut | May 2005 | B1 |
6902540 | Dorros et al. | Jun 2005 | B2 |
6905490 | Parodi | Jun 2005 | B2 |
6908474 | Hogendijk et al. | Jun 2005 | B2 |
6929634 | Dorros et al. | Aug 2005 | B2 |
6936060 | Hogendijk et al. | Aug 2005 | B2 |
6958059 | Zadno-Azizi | Oct 2005 | B2 |
6979346 | Hossainy et al. | Dec 2005 | B1 |
7004924 | Brugger et al. | Feb 2006 | B1 |
7004931 | Hogendijk | Feb 2006 | B2 |
7022100 | Aboul-Hosn et al. | Apr 2006 | B1 |
7029488 | Schonholz et al. | Apr 2006 | B2 |
7033344 | Imran | Apr 2006 | B2 |
7048758 | Boyle et al. | May 2006 | B2 |
7063714 | Dorros et al. | Jun 2006 | B2 |
7083594 | Coppi | Aug 2006 | B2 |
7108677 | Courtney et al. | Sep 2006 | B2 |
7223253 | Hogendijk | May 2007 | B2 |
7232452 | Adams et al. | Jun 2007 | B2 |
7232453 | Shimon | Jun 2007 | B2 |
7367982 | Nash et al. | May 2008 | B2 |
7374560 | Ressemann et al. | May 2008 | B2 |
7374561 | Barbut | May 2008 | B2 |
7422579 | Wahr et al. | Sep 2008 | B2 |
7458980 | Barbut | Dec 2008 | B2 |
7604612 | Ressemann et al. | Oct 2009 | B2 |
7879011 | Chang | Feb 2011 | B2 |
8002728 | Chang | Aug 2011 | B2 |
8308709 | Chang | Nov 2012 | B2 |
8343089 | Chang | Jan 2013 | B2 |
8414516 | Chang | Apr 2013 | B2 |
8870805 | Chang | Oct 2014 | B2 |
10286139 | Criado et al. | May 2019 | B2 |
20010044598 | Parodi | Nov 2001 | A1 |
20010044634 | Don Michael et al. | Nov 2001 | A1 |
20010049517 | Zadno-Azizi et al. | Dec 2001 | A1 |
20020052620 | Barbut | May 2002 | A1 |
20020052640 | Bigus et al. | May 2002 | A1 |
20020068899 | McGuckin et al. | Jun 2002 | A1 |
20020087119 | Parodi | Jul 2002 | A1 |
20020128679 | Turovskiy et al. | Sep 2002 | A1 |
20020173815 | Hogendijk et al. | Nov 2002 | A1 |
20030040762 | Dorros et al. | Feb 2003 | A1 |
20030050600 | Ressemann et al. | Mar 2003 | A1 |
20030065356 | Tsugita et al. | Apr 2003 | A1 |
20030069468 | Bolling et al. | Apr 2003 | A1 |
20030186203 | Aboud | Oct 2003 | A1 |
20030191474 | Cragg et al. | Oct 2003 | A1 |
20030212304 | Lattouf | Nov 2003 | A1 |
20040064179 | Linder et al. | Apr 2004 | A1 |
20040116946 | Goldsteen et al. | Jun 2004 | A1 |
20040127913 | Voss | Jul 2004 | A1 |
20040249435 | Andreas et al. | Dec 2004 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050124973 | Dorros et al. | Jun 2005 | A1 |
20050131453 | Parodi | Jun 2005 | A1 |
20050154344 | Chang | Jul 2005 | A1 |
20050154349 | Renz et al. | Jul 2005 | A1 |
20050228402 | Hofmann | Oct 2005 | A1 |
20050228432 | Hogendijk et al. | Oct 2005 | A1 |
20050267323 | Dorros et al. | Dec 2005 | A1 |
20050273051 | Coppi | Dec 2005 | A1 |
20060106338 | Chang | May 2006 | A1 |
20060149350 | Patel et al. | Jul 2006 | A1 |
20060167437 | Valencia | Jul 2006 | A1 |
20060200191 | Zadno-Azizi | Sep 2006 | A1 |
20070198049 | Barbut | Aug 2007 | A1 |
20070249997 | Goodson et al. | Oct 2007 | A1 |
20090024072 | Criado et al. | Jan 2009 | A1 |
20090254166 | Chou et al. | Oct 2009 | A1 |
20100042118 | Garrison et al. | Feb 2010 | A1 |
20130172852 | Chang | Jul 2013 | A1 |
20160271315 | Chang | Sep 2016 | A1 |
20160279379 | Chang | Sep 2016 | A1 |
20200108221 | Chang | Apr 2020 | A1 |
Number | Date | Country |
---|---|---|
101267781 | Sep 2008 | CN |
0427429 | May 1991 | EP |
1649829 | Apr 2006 | EP |
S59-161808 | Oct 1984 | JP |
H07-265412 | Oct 1995 | JP |
H08-071161 | Mar 1996 | JP |
10-052490 | Feb 1998 | JP |
H10-033666 | Feb 1998 | JP |
2003-521299 | Jul 2003 | JP |
2007-301326 | Nov 2007 | JP |
WO-9505209 | Feb 1995 | WO |
WO-9838930 | Sep 1998 | WO |
WO-9925419 | May 1999 | WO |
WO-9945835 | Sep 1999 | WO |
WO-9965420 | Dec 1999 | WO |
WO-0002617 | Jan 2000 | WO |
WO-0009028 | Feb 2000 | WO |
WO-0032266 | Jun 2000 | WO |
WO-0069350 | Nov 2000 | WO |
WO-0076390 | Dec 2000 | WO |
WO-0154588 | Aug 2001 | WO |
WO-0232495 | Apr 2002 | WO |
WO-03090831 | Nov 2003 | WO |
WO-2004006803 | Jan 2004 | WO |
WO-2005051206 | Jun 2005 | WO |
WO-2007136946 | Nov 2007 | WO |
WO-2009012473 | Jan 2009 | WO |
WO-2009099764 | Aug 2009 | WO |
WO-2009100210 | Aug 2009 | WO |
WO-2010019719 | Feb 2010 | WO |
PCTUS2020058365 | Oct 2020 | WO |
PCTUS2020058588 | Nov 2020 | WO |
PCTUS2020061073 | Nov 2020 | WO |
PCTUS2022033588 | Jun 2022 | WO |
PCTUS2022042074 | Aug 2022 | WO |
PCTUS2022044533 | Sep 2022 | WO |
PCTUS2022050714 | Nov 2022 | WO |
PCTUS2022051275 | Nov 2022 | WO |
PCTUS2022080992 | Dec 2022 | WO |
PCTUS2023061058 | Mar 2023 | WO |
PCTUS2023064772 | Mar 2023 | WO |
Entry |
---|
Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther. 9:147-154. |
Bates M.D., et al.(2003). “Reversal of the Direction of Internal Carotid Artery Blood Flow by Occlusion of the Common and External Carotid Arteries in a Swine Model” Catherization and Cardiovascular Intervention 60:270-275. |
Bates, M.D., et al. (2004) “Internal Carotid Artery Flow Arrest/Reversal Cerebral Protection Techniques” The West Virginal Medical Journal, vol. 99:60-63. |
Bergeron, P., et al. (1999, First Published May 1, 1999 Research Article). “Percutaneous Stenting of the Internal Carotid Artery: The European CAST I Study.” Journal of Endovascular Therapy. 6(2), 155-159. https://doi.org/10.1177/152660289900600207. |
Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79. |
Bettmann, M. et al., “Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association”. Circulation Journal of the American Heart Association. 1998. 97:121-123. Retrieved Feb. 16, 2012. |
Chang, D.W., et al., “A new approach to carotid angioplasty and stenting with transcervical occlusion and protective shunting: Why it may be a better carotid artery intervention” (J Vasc Surg 2004; 39:994-1002). |
Chang, M.D., “Carotid Angioplasty And Stenting Using Transcervical Occlusion And Protective Shunting Via A Mini Incision In The Neck: A New Technique For Difficult Femoral Access Or Filter Placement May Be The Better Carotid Artery Intervention” 30th Global: Vascular and Endovascular Issues, Techniques and Horizons Symposium, New York, NY, Nov. 20-23, 2003; XXVII 6.1-XXVII 6.2. |
Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114. |
Criado et al. (2004). “Transcervical carotid artery angioplasty and stenting with carotid flow reversal: Surgical technique” J. Vasc. Surg. 18:257-261. |
Criado et al. (2004). “Transcervical carotid stenting with internal carotid artery flow reversal: Feasibility and preliminary results” J. Vasc. Surg. 40:476-483. |
Criado, F.J., et al., Access strategies for carotid artery intervention. J Invasive Cardiol, 2000. 12(1): p. 61-8. |
Criado, M.D., et al. (2004) “Carotid angioplasty with internal carotid artery flow reversal is well tolerated in the awake patient” Journal of Vascular Surgery, 40(1):92-7. |
Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vasc. Endovasc. Surg. 28:629-633. |
Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202. |
Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136. |
Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331. |
MO.MA Brochure; Proximal Flow Blockage Cerebral Protection Device—INVATEC. |
Momapresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. |
Ohki, M.D., et al., “Efficacy of a proximal occlusion catheter with reversal of flow in the prevention of embolic events during carotid artery stenting: An experimental analysis” (J Vasc Surg 2001; 33:504-9). |
Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vasc Surg 34(4): 577-80. |
Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136. |
Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41. |
Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3. |
Stecker et al., (2002). “Stent placement in common carotid and internal carotid artery stenoses with use of an open transcervical approach in a patient with previous endarterectomy” J. Vasc. Interv. Radiol. 13:413-417. |
Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection.” AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology. |
U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512. |
U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, US 2019-0388654. |
U.S. Appl. No. 16/297,348, filed Mar. 8, 2019, US 2020-0038576. |
U.S. Appl. No. 16/299,524, filed Mar. 12, 2019, US 2019-0366070. |
U.S. Appl. No. 16/353,492, filed Mar. 14, 2019, US 2020-0009406. |
U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962. |
U.S. Appl. No. 16/513,030, filed Jul. 16, 2019, US 2020-0170637. |
U.S. Appl. No. 16/544,083, filed Aug. 19, 2019, US 2020-0171277. |
U.S. Appl. No. 16/880,594, filed May 21, 2020, US 2020-0282127. |
U.S. Appl. No. 17/092,635, filed Nov. 9, 2020, US 2021-0228847. |
U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769. |
U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764. |
U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260. |
U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, US 2020-0054871. |
U.S. Appl. No. 16/894,474, filed Jun. 5, 2020, US 2020-0297912. |
U.S. Appl. No. 16/906,457, filed Jun. 19, 2020, US 2020-0397472. |
U.S. Appl. No. 16/939,396, filed Jul. 27, 2020, US 2020-0397446. |
U.S. Appl. No. 16/951,767, filed Nov. 18, 2020, US 2021-0145453. |
U.S. Appl. No. 16/999,634, filed Aug. 21, 2020, US 2020-0375728. |
U.S. Appl. No. 16/999,640, filed Aug. 21, 2020, US 2020-0375729. |
U.S. Appl. No. 17/000,004, filed Aug. 21, 2020, US 2020-0390438. |
U.S. Appl. No. 17/074,299, filed Oct. 19, 2020, US 2021-0205571. |
U.S. Appl. No. 17/108,711, filed Dec. 1, 2020, US 2021-0212679. |
U.S. Appl. No. 17/149,450, filed Jan. 14, 2021, US 2021-0298929. |
U.S. Appl. No. 17/179,746, filed Feb. 19, 2021, US 2021-0244522. |
U.S. Appl. No. 17/193,962, filed Mar. 5, 2021, US 2021-0290257. |
U.S. Appl. No. 17/206,665, filed Mar. 19, 2021, US 2021-0307945. |
U.S. Appl. No. 17/220,718, filed Apr. 1, 2021, US 2021-0290213. |
U.S. Appl. No. 17/237,911, filed Apr. 22, 2021, US 2021-0236790. |
U.S. Appl. No. 17/307,359, filed May 4, 2021, US 2021-0322738. |
U.S. Appl. No. 17/345,502, filed Jun. 11, 2021, US 2021-0299343. |
U.S. Appl. No. 17/345,544, filed Jun. 11, 2021, US 2021-0299425. |
U.S. Appl. No. 17/398,969, filed Aug. 10, 2021, US 2022-0047267. |
U.S. Appl. No. 17/406,822, filed Aug. 19, 2021, US 2022-0040502. |
U.S. Appl. No. 17/470,213, filed Sep. 9, 2021, US 2022-0202552. |
U.S. Appl. No. 17/555,127, filed Dec. 17, 2021, US 2022-0193321. |
U.S. Appl. No. 17/684,745, filed Mar. 2, 2022, US 2023-0045964. |
U.S. Appl. No. 17/749,423, filed May 20, 2022, US 2023-0001161. |
U.S. Appl. No. 17/749,454, filed May 20, 2022, US 2023-0097442. |
U.S. Appl. No. 17/773,200, filed Apr. 29, 2022, US 2022-0401111. |
U.S. Appl. No. 17/773,206, filed Apr. 29, 2022, US 2022-0378565. |
U.S. Appl. No. 17/899,279, filed Aug. 30, 2022, US 2023-0067426. |
U.S. Appl. No. 17/951,727, filed Sep. 23, 2022, US 2023-0101242. |
U.S. Appl. No. 18/071,323, filed Nov. 29, 2022, US 2023-0165696. |
Number | Date | Country | |
---|---|---|---|
20210251634 A1 | Aug 2021 | US |
Number | Date | Country | |
---|---|---|---|
60587067 | Jul 2004 | US | |
60569843 | May 2004 | US | |
60524069 | Nov 2003 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16939396 | Jul 2020 | US |
Child | 17308199 | US | |
Parent | 16581034 | Sep 2019 | US |
Child | 16939396 | US | |
Parent | 16256229 | Jan 2019 | US |
Child | 16581034 | US | |
Parent | 15168786 | May 2016 | US |
Child | 16256229 | US | |
Parent | 14622310 | Feb 2015 | US |
Child | 15168786 | US | |
Parent | 14508354 | Oct 2014 | US |
Child | 14622310 | US | |
Parent | 12966974 | Dec 2010 | US |
Child | 14508354 | US | |
Parent | 10996301 | Nov 2004 | US |
Child | 12966974 | US |